These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6339039)

  • 1. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases.
    Durden DL; Salazar AM; Distasio JA
    Cancer Res; 1983 Apr; 43(4):1602-5. PubMed ID: 6339039
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
    Roberts J; Schmid FA; Old LJ; Stockert E
    Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the L-asparaginases from Escherichia coli and Erwinia carotovora as immunosuppressants.
    Ashworth LA; MacLennan AP
    Cancer Res; 1974 Jun; 34(6):1353-9. PubMed ID: 4596965
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes.
    Durden DL; Distasio JA
    Cancer Res; 1980 Apr; 40(4):1125-9. PubMed ID: 6986981
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxic and immunodepressive effects of L-asparaginase from E. coli and from Erwinia carotovora following chronic administration in rats.
    Celle G; Dodero M; Cuneo P; Picciotto A; Brambilla G; Cavanna M; Pannaciulli I
    Arzneimittelforschung; 1977; 27(11):2046-50. PubMed ID: 341899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative experimental evaluation of immunodepressive and toxic effects of L-asparaginase (NSC-109229) from Escherichia coli and from Erwinia carotovora.
    Cavanna M; Celle G; Dodero M; Picciotto A; Pannacciulli I; Brambilla G
    Cancer Treat Rep; 1976 Mar; 60(3):255-7. PubMed ID: 769978
    [No Abstract]   [Full Text] [Related]  

  • 7. Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity.
    Distasio JA; Salazar AM; Nadji M; Durden DL
    Int J Cancer; 1982 Sep; 30(3):343-7. PubMed ID: 6752048
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antigenic properties of 1-asparaginases isolated from different species and strains of bacteria].
    Chaĭkovskaia SM; Makarova RA; Tochenaia NP; Frolova MA
    Antibiotiki; 1976 Mar; 21(3):255-8. PubMed ID: 776078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The toxicity of Escherichia coli L-asparaginase.
    Schein PS; Rakieten N; Gordon BM; Davis RD; Rall DP
    Cancer Res; 1969 Feb; 29(2):426-34. PubMed ID: 4975316
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bacterial L-asparaginase and glutamin(asparagin)ase: some properties, structure and anti-tumor activity].
    Sokolov NN; Zanin VA; Aleksandrova SS
    Vopr Med Khim; 2000; 46(6):531-48. PubMed ID: 11234278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice.
    Bendich A; Kafkewitz D; Abuchowski A; Davis FF
    Clin Exp Immunol; 1982 Apr; 48(1):273-8. PubMed ID: 7044632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and pharmacological characterization of poly-DL-alanyl-modified Erwinia carotovora L-asparaginase.
    Uren JR; Hargis BJ; Beardsley P
    Cancer Res; 1982 Oct; 42(10):4068-71. PubMed ID: 7105004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of Erwinia carotovora and Escherichia coli L-asparaginases and their subunits.
    Miller DS; Marlborough DI; Cammack KA
    J Gen Microbiol; 1971 Mar; 65(3):ii. PubMed ID: 4933808
    [No Abstract]   [Full Text] [Related]  

  • 14. One-step purification and kinetic properties of the recombinant L-asparaginase from Erwinia carotovora.
    Krasotkina J; Borisova AA; Gervaziev YV; Sokolov NN
    Biotechnol Appl Biochem; 2004 Apr; 39(Pt 2):215-21. PubMed ID: 15032742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some physicochemical aspects of L-asparaginase therapy.
    Mashburn LT; Landin LM
    Recent Results Cancer Res; 1970; 33():48-63. PubMed ID: 4949169
    [No Abstract]   [Full Text] [Related]  

  • 18. The modification of tyrosyl residues in L-asparaginases and ribonuclease a with Fremy's salt. Implication of tyrosyl residues in the activity of L-asparaginases from E. coli B and Erwinia carotovora.
    Homer RB; Allsopp SR; Arrieta JE
    FEBS Lett; 1975 Nov; 59(2):173-6. PubMed ID: 776662
    [No Abstract]   [Full Text] [Related]  

  • 19. Alteration in spleen lymphoid populations associated with specific amino acid depletion during L-asparaginase treatment.
    Distasio JA; Durden DL; Paul RD; Nadji M
    Cancer Res; 1982 Jan; 42(1):252-8. PubMed ID: 7032693
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of different techniques for isoelectric focusing on polyacrylamide gel slabs using bacterial asparaginases.
    Robinson HK
    Anal Biochem; 1972 Oct; 49(2):353-66. PubMed ID: 4563222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.